

Risk Factors for Mortality in Patients with Carbapenem-Resistant *Acinetobacter baumannii* Bacteremia: Impact of Appropriate Antimicrobial Therapy

Youn Jeong Kim¹, Sang Il Kim¹,
Kyung-Wook Hong¹, Yang Ree Kim¹,
Yeon Joon Park², and Moon-Won Kang¹

Departments of ¹Internal Medicine and ²Laboratory Medicine, The Catholic University of Korea College of Medicine, Seoul, Korea

Received: 1 August 2011
Accepted: 27 January 2012

Address for Correspondence:
Yang Ree Kim, MD

Department of Internal Medicine, Uijeongbu St. Mary's Hospital, The Catholic University of Korea College of Medicine, 271 Cheonbo-ro, Uijeongbu 480-717, Korea
Tel: +82.31-820-3798, Fax: +82.31-847-2719
E-mail: yrkim@catholic.ac.kr

This study investigated predictors associated with 14-day mortality, and focused especially on the impact of appropriate antimicrobial treatment among patients with carbapenem-resistant *Acinetobacter baumannii* (CRAB) bacteremia. This retrospective study was performed at a tertiary care hospital in Korea from June 2007 to June 2010. Antibiotic therapy was considered appropriate if the antibiotics were administered via an appropriate route within 24 hr after the result of blood culture, had in vitro sensitivity to isolated strains, and of an adequate dosage according to the current guidelines. Ninety-five patients with *A. baumannii* bacteremia were included; of these, 53 (55.8%) were infected with CRAB. The overall infection-related 14-day mortality was higher in patients receiving inappropriate antimicrobial therapy than in patients receiving appropriate therapy (59.5% [22/37] vs 13.8% [8/58], $P < 0.05$). Multivariate analysis showed that septic shock (OR 10.5, 95% CI, 1.93-57.4; $P = 0.006$), carbapenem-resistance (OR 7.29, 95% CI 1.57-33.8; $P = 0.01$), pneumonia as a source of bacteremia (OR 5.29, 95% CI 1.07-26.1; $P = 0.04$), and inappropriate antimicrobial therapy (OR 8.05, 95% CI 1.65-39.2; $P = 0.009$) were independent risk factors for 14-day mortality. Early definite antimicrobial therapy had an influence on favorable outcomes in patients with *A. baumannii* bacteremia.

Key Words: *Acinetobacter baumannii*; Risk Factors; Carbapenem-Resistance; Mortality

INTRODUCTION

Acinetobacter baumannii is an important nosocomial pathogen (1-6). Carbapenem is a preferred drug of choice for the treatment of multidrug-resistant *A. baumannii*. However, carbapenem-resistant strains have now emerged around the world (2). Prevalence of carbapenem-resistant *A. baumannii* varies in different countries; in Korea, the resistance rate of *A. baumannii* against carbapenem was reported as 31.7% or 34.9% (7).

A. baumannii may cause various clinical manifestations ranging from colonization to septic shock, and *A. baumannii* bacteremia-associated mortality rate is reported to be as high as 17%-62% (8-10). Initiation of effective empirical antimicrobial treatment might be important for reducing *A. baumannii* bacteremia-associated mortality. However, in Korea, initiation of broad spectrum antibiotic treatment with antibiotics such as carbapenem or colistin is difficult because of insurance problems (11, 12). Because the severity of underlying disease could affect the outcomes in patients with *A. baumannii* bacteremia, it is not yet clear whether immediate and appropriate antimicrobial therapy as proper dose and administration route can affect these outcomes (12, 13). Because of the presence of limited therapeutic

options for carbapenem-resistant *A. baumannii* (CRAB), it is important to understand the factors responsible for the development of carbapenem-resistance and the risk factors associated with mortality. In this study, we investigated the factors associated with acquisition of CRAB in patients with *A. baumannii* bacteremia; and the predictors associated with 14-day mortality. Our study especially focused on the impact of early and appropriate antimicrobial treatment after obtaining culture results.

MATERIALS AND METHODS

Study design

A retrospective study was performed from June 2007 to June 2010 at a tertiary care hospital with 1,200 beds in Korea. All patients over 16-yr old from whom *A. baumannii* was isolated from at least one set of blood cultures with definite clinical signs of infection were enrolled. Only the first bacteremic episode from each patient was included in this study. Antibiotic therapy was considered appropriate if the antibiotics administered via an appropriate route within 24 hr of blood culture results showed an in vitro effectiveness against isolated strains, and if the dos-

age was adequate according to the current guidelines. Infection was assessed according to "Centers for Disease Control and Prevention" criteria, and patients were considered infected when *A. baumannii* was isolated from a sterile site in patients with definite clinical signs of infection (14). Prior antibiotics treatment was defined as the use of systemic antibiotics for at least 7 days within the preceding 28 days. For better understanding of the patients' baseline status, we assessed the APACHE II score before bacteremia on the date of admission. We used 14-day in-hospital mortality as the main outcome for assessment of mortality for patients with serious conditions due to bacteremia.

Microbiological examination

Identification of *A. baumannii* in blood samples was performed using a VITEK[®]2 automated system (bioMérieux, Marcy l'Etoile, France). Susceptibility results were interpreted according to guidelines established by the Clinical and Laboratory Standards Institute (15). CRAB was defined as non-susceptible to meropenem and/or imipenem in vitro, and isolates with intermediate resistance were regarded as resistance.

Statistically analysis

Student's t-test was used for analysis of continuous variables, and the chi-squared test or Fisher's exact test was used for categorical variables and Student's t test or the Mann-Whitney U test for continuous variables. We analyzed the risk factors associated with mortality using univariate and multivariate logistic regression analyses. Survival curves were prepared using the Kaplan-Meier method with log-rank test. Statistical analysis was performed using SPSS 13.0 and a *P* value < 0.05 was considered statistically significant.

Ethics statement

This study was approved by the institutional review board of Seoul St. Mary's Hospital (Protocol No; KC10OIS10070). Informed consent was waived by the board. All the data collected during this study were kept confidential.

RESULTS

A total of 95 patients with *A. baumannii* bacteremia were included in this study. Demographic characteristics of these pa-

Table 1. Clinical characteristics of patients with *Acinetobacter baumannii* bacteremia

Parameters	Total (n = 95)	CRAB group (n = 53)	Non-CRAB group (n = 42)	<i>P</i> value
Age, mean ± SD (yr)	58.4 ± 20.9	59.4 ± 21.8	57.1 ± 19.9	0.59
Male sex	51 (53.7%)	33 (62.3%)	18 (42.9%)	0.06
Underlying disease				
Diabetes mellitus	21 (22.1%)	16 (30.2%)	5 (11.9%)	0.04
Hypertension	21 (22.1%)	14 (26.4%)	7 (16.7%)	0.3
Liver cirrhosis	11 (11.6%)	7 (13.2%)	4 (9.5%)	0.75
Transplant	7 (7.4%)	6 (11.3%)	1 (2.4%)	0.12
Malignancy	50 (52.6%)	28 (52.8%)	22 (52.4%)	0.99
Dialysis	16 (16.8%)	13 (24.5%)	3 (7.1%)	0.03
Immunosuppression	22 (23.2%)	14 (26.4%)	8 (19.0%)	0.47
Previous surgery within one month	45 (47.4%)	25 (47.2%)	20 (47.6%)	0.96
Hospitalization in the preceding 90 days	43 (45.3%)	25 (47.2%)	18 (42.9%)	0.68
Invasive procedure				
Central venous catheter	61 (64.2%)	37 (69.8%)	24 (68.5%)	0.28
Surgical drainage	31 (32.6%)	18 (34.0%)	13 (30.9%)	0.8
Foley catheter	50 (52.6%)	34 (64.2%)	16 (38.1%)	0.02
Tracheostomy	13 (13.7%)	9 (17.0%)	4 (9.5%)	0.31
Mechanical ventilation	29 (30.5%)	23 (43.4%)	6 (14.3%)	0.003
The length of stay before bacteremia, mean ± SD	30.2 ± 51.5	30.0 ± 33.3	30.4 ± 68.3	0.96
APACHE II score	12.4 ± 7.3	14.4 ± 7.7	10.4 ± 6.1	0.005
Charlson's weighted index of co-morbidity	2.7 ± 2.1	2.8 ± 1.9	2.5 ± 2.4	0.42
Prior antibiotics				
Cephalosporin	44 (46.3%)	17 (32.1%)	27 (64.3%)	0.002
Quinolone	11 (11.6%)	6 (11.3%)	5 (11.9%)	0.93
Aminoglycoside	7 (7.4%)	2 (3.8%)	5 (11.9%)	0.13
Carbapenem	28 (29.5%)	26 (49.1%)	2 (4.8%)	0.001
Source of bacteremia				
Pneumonia	28 (29.5%)	17 (32.1%)	11 (26.2%)	0.65
Urinary tract	6 (6.3%)	2 (3.8%)	4 (9.5%)	0.25
Vascular catheter-related	24 (25.3%)	12 (22.6%)	12 (28.6%)	0.51
Intra-abdomen	15 (15.8%)	9 (17.0%)	6 (14.3%)	0.72
Postoperative wound	8 (8.4%)	6 (11.3%)	2 (4.8%)	0.25
Unknown	8 (8.4%)	1 (1.9%)	7 (16.7%)	0.02

CRAB, carbapenem-resistant *Acinetobacter baumannii*.

tients are shown in Table 1. The mean age of the patients was 58.4 ± 20.9 yr, and of the 95 patients, 53.7% were male. The mean length of stay before *A. baumannii* bacteremia was 30.2 ± 51.5 days. The presumed sources of bacteremia were respiratory tract ($n = 28, 29.5\%$), vascular catheter ($n = 24, 25.3\%$), intra-abdomen ($n = 15, 15.8\%$), postoperative wounds ($n = 8, 8.4\%$), urinary tract ($n = 6, 6.3\%$), and other unknown sources ($n = 8, 8.4\%$).

Fifty-three patients (55.8%) were infected with CRAB. Univariate analysis showed that the risk factors for acquisition of CRAB bacteremia were diabetes mellitus (OR 3.2, 95% CI 1.06-9.64; $P = 0.04$), dialysis (OR 4.23, 95% CI 1.11-15.9; $P = 0.03$) as an underlying disease, use of foley catheter (OR 2.91, 95% CI 1.26-6.73; $P = 0.01$), mechanical ventilation support (OR 4.6, 95% CI 1.66-12.77; $P = 0.003$), and prior use of cephalosporin (OR 3.81, 95% CI 1.62-8.96; $P = 0.002$) or carbapenem (OR 19.3, 95% CI 4.21-87.9; $P = 0.001$). By multivariate analysis, diabetes mellitus as an underlying disease (OR 4.51, 95% CI 1.16-14.8; $P = 0.03$) and prior use of carbapenem (OR 14.8, 95% CI 2.76-79.5; $P = 0.002$) were independently associated with CRAB bacteremia (Table 2).

The overall infection-related 14-day mortality in patients with *A. baumannii* bacteremia was 31.6% (30/95); infection-related 14-day mortality was higher in patients receiving inappropriate antimicrobial therapy than in patients receiving appropriate therapy (59.5% [22/37] vs 13.8% [8/58], $P < 0.05$). The cumulative survival curves of the patients according to the appropriateness of antimicrobial therapy are shown in Fig. 1. Univariate analysis showed that the risk factors for infection-related 14-day mor-

tality in patients with *A. baumannii* bacteremia were central venous catheter (OR 4.02, 95% CI 1.37-11.83; $P = 0.01$), mechanical ventilator (OR 5.77, 95% CI 2.22-15.02; $P < 0.001$), high APACHE II score (OR 4.01, 95% CI 1.39-11.4; $P = 0.01$), septic shock (OR 5.61, 95% CI 2.13-14.7; $P < 0.001$), carbapenem-resistance (OR 9.14, 95% CI 2.86-29.2; $P < 0.001$), pneumonia as a source of bacteremia (OR 5.05, 95% CI 1.94-13.0; $P < 0.001$), and inappropriate antibiotic therapy (OR 6.58, 95% CI 2.53-17.1; $P < 0.001$) (Table 3). Multivariate analysis showed that septic shock (OR 10.5, 95% CI 1.93-57.4; $P = 0.006$), carbapenem-resistance




Fig. 1. Survival curve according to the appropriateness of antimicrobial therapy.

Table 2. Risk factors for acquisition of carbapenem resistant *Acinetobacter baumannii* bacteremia

Risk factors	Univariate analysis			Multivariate analysis		
	OR	95% CI	P value	OR	95% CI	P value
Age, mean \pm SD	1.0	0.99-1.02	0.59			
Male sex	2.2	0.96-5.02	0.06			
Underlying disease						
Diabetes mellitus	3.2	1.06-9.64	0.04	4.51	1.16-14.8	0.03
Hypertension	1.79	0.65-4.95	0.3			
Liver cirrhosis	1.44	0.39-5.31	0.56			
Transplant	5.23	0.61-45.3	0.12			
Malignancy	1.01	0.45-2.29	0.95			
Dialysis	4.23	1.11-15.9	0.03	1.48	0.27-7.7	0.66
Immunosuppression	1.53	0.57-4.10	0.40			
Previous surgery within one month	1.01	0.45-2.29	0.96			
Hospitalization in the preceding 90 days	1.19	0.52-2.69	0.68			
Invasive procedure						
Central venous catheter	1.74	0.74-4.10	0.21			
Surgical drainage	1.14	0.48-2.73	0.76			
Foley catheter	2.91	1.26-6.73	0.01	2.51	0.89-7.59	0.08
Tracheostomy	1.94	0.54-6.81	0.31			
Mechanical ventilation	4.6	1.66-12.77	0.003	2.75	0.77-9.62	0.12
The length of stay before bacteremia, mean \pm SD	1	0.99-1.00	0.96			
Prior antibiotics						
Cephalosporin	3.81	1.62-8.96	0.002	1.85	0.61-5.61	0.27
Quinolone	1.05	0.29-3.74	0.93			
Aminoglycoside	3.44	0.63-18.7	0.15			
Carbapenem	19.3	4.21-87.9	0.001	14.8	2.76-79.5	0.002

CRAB, carbapenem-resistant *Acinetobacter baumannii*.

Table 3. Risk factors associated with 14-day mortality in patients with *Acinetobacter baumannii* bacteremia

Risk factors	Univariate analysis			Multivariate analysis		
	OR	95% CI	P value	OR	95% CI	P value
Age \geq 60 yr	1.48	0.61-3.6	0.38			
Diabetes mellitus	2.45	0.90-6.66	0.07			
Malignancy	1.72	0.72-4.13	0.21			
Mechanical ventilator	5.77	2.22-15.0	< 0.001	1.59	0.39-6.41	0.51
Central venous catheter	4.02	1.37-11.8	0.01	3.53	0.68-18.2	0.13
APACHE II score \geq 14	4.01	1.39-11.4	0.01	1.67	0.36-7.79	0.5
Septic shock	5.61	2.13-14.7	< 0.001	10.5	1.93-57.4	0.006
CR	9.14	2.86-29.2	< 0.001	7.29	1.57-33.8	0.01
Pneumonia as a source of bacteremia	5.05	1.94-13.0	0.001	5.29	1.07-26.1	0.04
Inappropriate antibiotic therapy	6.58	2.53-17.1	< 0.001	8.05	1.65-39.2	0.009

OR, odds ratio; CI, confidential interval; CR, carbapenem-resistance.

(OR 7.29, 95% CI 1.57-33.8; $P = 0.01$), pneumonia as a source of bacteremia (OR 5.29, 95% CI 1.07-26.1; $P = 0.04$), and inappropriate antimicrobial therapy (OR 8.05, 95% CI 1.65-39.2; $P = 0.009$) were the independent risk factors for 14-day mortality (Table 3). In sub-analysis of the CRAB group, patients receiving inappropriate antimicrobial therapy showed a higher mortality than those receiving appropriate therapy (67.9% [19/28] vs 28.0% [7/25], $P = 0.004$). In the non-CRAB group, 33 patients received appropriate therapy and 97% of the patients had survived for 14 days after the onset of bacteremia.

DISCUSSION

A. baumannii is usually a healthcare-associated pathogen and is emerging as a cause of numerous global outbreaks (1, 2). Antimicrobial resistance recently has emerged as an important problem. Carbapenem is widely used for the treatment of multidrug-resistant *A. baumannii* infections, however, reports of CRAB are also increasing worldwide.

Previous studies have showed that factors associated with mortality in patients with *A. baumannii* infection are septic shock, age, severity of the underlying disease, and mechanical ventilation (16-18). Delay in receiving empirical antimicrobial therapy has an adverse effect on clinical outcomes, however, some studies have shown that severity of illness is a more important factor for mortality than empirical therapy in hospital-acquired pneumonia caused by *A. baumannii* (12, 19). Moreover, in Korea, use of broad spectrum antibiotics prior to the isolation of multidrug-resistant strains is limited.

Our study revealed that independent risk factors associated with 14-day mortality in patients with *A. baumannii* bacteremia included septic shock, carbapenem-resistance, pneumonia as a source of bacteremia and inappropriate antibiotic therapy. This study evaluated the clinical outcomes in patients with *A. baumannii* bacteremia according to the inappropriateness of antibiotics (i.e., antibiotics that were not active in vitro and those that were administered as an improper dose or through an im-

proper route) after obtaining the blood culture results. Our data suggest that early administration of appropriate antimicrobial therapy showed improved outcomes in patients with CRAB bacteremia, although underlying status played an important role in clinical outcome.

Studies have shown that APACHE II score is useful for the estimation of prognosis in *Acinetobacter* pneumonia (19, 20). In our study, a high APACHE II score was associated with mortality by univariate analysis; however this was not identified as an independent risk factor by multivariate analysis. This may be because of several reasons. First, some information, such as that on sepsis and mechanical ventilation, was not included while determining this score. Second, we assessed the APACHE II score before the occurrence of bacteremia on the date of admission, in order to best reflect the patients' baseline status. Our study also showed that septic shock at the time of bacteremia was an independent risk factor for mortality. This finding suggested that a combination of other parameters, including the APACHE II score, is necessary for the evaluation of morbidity in patients with bacteremia.

The effect of antibiotic resistance on mortality is controversial. Some studies have reported that antibiotic resistance has an adverse impact on the mortality rates in patients with *A. baumannii* bacteremia (1, 21). One study reported that mortality in patients with multidrug-resistant *A. baumannii* infection in surgical intensive care units did not differ significantly from that in patients with non-multidrug-resistant *A. baumannii* infection. However, the study did not include patients who were simply bacteremic (6). Our results showed that carbapenem resistance was independently associated with mortality. However, patients with CRAB bacteremia had a higher APACHE II score (14.4 ± 7.7 vs 10.4 ± 6.1 , $P = 0.005$) and received a more inappropriate antibiotic treatment (52.8% [28/53] vs 21.4% [9/42], $P = 0.002$) than those with non-CRAB bacteremia. CRAB bacteremia usually occurs in patients with severe illness and in patients with a high probability of receiving inappropriate antimicrobial therapy, which then negatively affect the outcomes.

Results from the present study also showed that factors for acquisition of CRAB included diabetes mellitus as an underlying disease and a prior exposure to carbapenem. Some studies have reported that prior use of carbapenem, third-generation cephalosporins and fluoroquinolones are independent risk factors for the acquisition of multidrug resistant *A. baumannii* (22, 23). Selective pressure exerted by use of broad spectrum antibiotics, such as carbapenem, leads to the emergence of multidrug-resistant *A. baumannii*. Therefore, we consider multidrug resistance in patients with *A. baumannii* bacteremia who showed particularly severe illness, and who had recently received carbapenem. In order to decrease acquisition of CRAB, judicious use of carbapenem is important.

Our study had some limitations, including the retrospective design, which was not randomized. A small number of patients were enrolled from a single center. Furthermore, we could not judge the appropriateness of the empirical antibiotic treatment in this study. It was rare that patients with CRAB bacteremia received colistin empirically, because of insurance or restriction of broad spectrum antibiotics for policy of antibiotics control. However, our study should encourage clinicians not to delay definite antimicrobial treatment in patients with *A. baumannii* bacteremia.

In conclusion, patients with *A. baumannii* bacteremia receiving early and appropriate antimicrobial therapy are expected to show favorable outcomes, although the status of underlying disease also plays an important role in the clinical outcomes.

REFERENCES

- Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA. Global challenge of multidrug-resistant *Acinetobacter baumannii*. *Antimicrob Agents Chemother* 2007; 51: 3471-84.
- Dijkshoorn L, Nemeč A, Seifert H. An increasing threat in hospitals: multidrug-resistant *Acinetobacter baumannii*. *Nat Rev Microbiol* 2007; 5: 939-51.
- Ayan M, Durmaz R, Aktas E, Durmaz B. Bacteriological, clinical and epidemiological characteristics of hospital-acquired *Acinetobacter baumannii* infection in a teaching hospital. *J Hosp Infect* 2003; 54: 39-45.
- Paul M, Weinberger M, Siegman-Igra Y, Lazarovitch T, Ostfeld I, Boldur I, Samra Z, Shula H, Carmeli Y, Rubinovitch B, et al. *Acinetobacter baumannii*: emergence and spread in Israeli hospitals 1997-2002. *J Hosp Infect* 2005; 60: 256-60.
- Navon-Venezia S, Ben-Ami R, Carmeli Y. Update on *Pseudomonas aeruginosa* and *Acinetobacter baumannii* infections in the healthcare setting. *Curr Opin Infect Dis* 2005; 18: 306-13.
- Daniels TL, Deppen S, Arbogast PG, Griffin MR, Schaffner W, Talbot TR. Mortality rates associated with multidrug-resistant *Acinetobacter baumannii* infection in surgical intensive care units. *Infect Control Hosp Epidemiol* 2008; 29: 1080-3.
- Park YK, Peck KR, Cheong HS, Chung DR, Song JH, Ko KS. Extreme drug resistance in *Acinetobacter baumannii* infections in intensive care units, South Korea. *Emerg Infect Dis* 2009; 15: 1325-7.
- Robenshtok E, Paul M, Leibovici L, Fraser A, Pitlik S, Ostfeld I, Samra Z, Perez S, Lev B, Weinberger M. The significance of *Acinetobacter baumannii* bacteraemia compared with *Klebsiella pneumoniae* bacteraemia: risk factors and outcomes. *J Hosp Infect* 2006; 64: 282-7.
- Jerassy Z, Yinnon AM, Mazouz-Cohen S, Benenson S, Schlesinger Y, Rudensky B, Raveh D. Prospective hospital-wide studies of 505 patients with nosocomial bacteraemia in 1997 and 2002. *J Hosp Infect* 2006; 62: 230-6.
- Grupper M, Sprecher H, Mashlach T, Finkelstein R. Attributable mortality of nosocomial *Acinetobacter* bacteremia. *Infect Control Hosp Epidemiol* 2007; 28: 293-8.
- Harbarth S, Garbino J, Pugin J, Romand JA, Lew D, Pittet D. Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. *Am J Med* 2003; 115: 529-35.
- Erbay A, Idil A, Gözel MG, Mumcuoğlu I, Balaban N. Impact of early appropriate antimicrobial therapy on survival in *Acinetobacter baumannii* bloodstream infections. *Int J Antimicrob Agents* 2009; 34: 575-9.
- Lim SK, Lee SO, Choi SH, Choi JP, Kim SH, Jeong JY, Choi SH, Woo JH, Kim YS. The outcomes of using colistin for treating multidrug resistant *Acinetobacter* species bloodstream infections. *J Korean Med Sci* 2011; 26: 325-31.
- Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. *Am J Infect Control* 1988; 16: 128-40.
- Clinical and Laboratory Standards Institute. *Performance Standards for Antimicrobial Susceptibility Testing Informational Supplement M100-S16*. Wayne: Clinical and Laboratory Standards Institute, 2008.
- Choi JY, Park YS, Kim CO, Yoon HJ, Shin SY, Kim YA, Song YG, Yong D, Lee K, Kim JM. Mortality risk factors of *Acinetobacter baumannii* bacteraemia. *Intern Med J* 2005; 35: 599-603.
- Tilley PA, Roberts FJ. Bacteremia with *Acinetobacter* species: risk factors and prognosis in different clinical settings. *Clin Infect Dis* 1994; 18: 896-900.
- Chen HP, Chen TL, Lai CH, Fung CP, Wong WW, Yu KW, Liu CY. Predictors of mortality in *Acinetobacter baumannii* bacteremia. *J Microbiol Immunol Infect* 2005; 38: 127-36.
- Joung MK, Kwon KT, Kang CI, Cheong HS, Rhee JY, Jung DS, Chung SM, Lee JA, Moon SY, Ko KS, et al. Impact of inappropriate antimicrobial therapy on outcome in patients with hospital-acquired pneumonia caused by *Acinetobacter baumannii*. *J Infect* 2010; 61: 212-8.
- Garnacho-Montero J, Ortiz-Leyba C, Fernández-Hinojosa E, Aldabó-Pallás T, Cayuela A, Marquez-Vácaro JA, García-Curiel A, Jiménez-Jiménez FJ. *Acinetobacter baumannii* ventilator-associated pneumonia: epidemiological and clinical findings. *Intensive Care Med* 2005; 31: 649-55.
- Kwon KT, Oh WS, Song JH, Chang HH, Jung SI, Kim SW, Ryu SY, Heo ST, Jung DS, Rhee JY, et al. Impact of imipenem resistance on mortality in patients with *Acinetobacter* bacteraemia. *J Antimicrob Chemother* 2007; 59: 525-30.
- Ye JJ, Huang CT, Shie SS, Huang PY, Su LH, Chiu CH, Leu HS, Chiang PC. Multidrug resistant *Acinetobacter baumannii*: risk factors for appearance of imipenem resistant strains on patients formerly with susceptible strains. *PLoS One* 2010; 5: e9947.
- Falagas ME, Kopterides P. Risk factors for the isolation of multi-drug-resistant *Acinetobacter baumannii* and *Pseudomonas aeruginosa*: a systematic review of the literature. *J Hosp Infect* 2006; 64: 7-15.